MBX Biosciences, focused on peptide therapeutics for metabolic diseases, recorded a net loss of $86.97 million in 2025 amid intensifying R&D and operational expenses. The company’s cash reserves of approximately $75.3 million support ongoing operations into 2029 under current plans. Its clinical pipeline includes three main candidates, with plans to add two obesity-related therapies in 2026. MBX relies on exclusive intellectual property licensed from Indiana University Research and Technology Corporation, forming a core competitive asset. While facing typical biotech risks including regulatory uncertainties and capital requirements, recent insider buying signals management confidence despite market caution.